Serum resistin is predictive marker of development of new digital ulcers in systemic sclerosis.


Journal

Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 24 05 2021
accepted: 19 08 2021
pubmed: 1 9 2021
medline: 3 8 2022
entrez: 31 8 2021
Statut: ppublish

Résumé

Systemic sclerosis (SSc) is autoimmune disease characterized by endothelial dysfunction and microvascular damage. Resistin has been implied in microvascular dysfunction. Objective of this study is to evaluate the association between baseline resistin and development of new digital ulcers (DUs) in SSc patients. At baseline, serum resistin has been assessed in 70 female SSc patients and 26 healthy controls (HC). In SSc patients, clinical assessment was performed at baseline and after a 52-weeks follow-up. Serum resistin level was increased in SSc patients compared to HC [5.89 ng/ml (2.5 ng/ml-8.1 ng/ml) vs 2.3 ng/ml (0.4 ng/ml-2.4 ng/ml), p = 0.0004)]. Resistin was lower (p = 0.005) in SSc patients with early capillaroscopic pattern than patients with active or late capillaroscopic pattern [2.49 ng/ml (0.89 ng/ml-5.81 ng/ml) vs 7.11 ng/ml (3.48 ng/ml-11.35 ng/ml) and 6.49 ng/ml (3.35 ng/ml-8.87 ng/ml), respectively]. After a 52-weeks follow-up, 34 (48.6%) patients developed new DUs. Median serum resistin was significantly higher in patients with new DUs than in patients without new DUs [6.54 ng/ml (3.35 ng/ml-11.02 ng/ml) vs 4.78 ng/ml (1.06 ng/ml-7.6 ng/ml), p = 0.019]. Kaplan-Meier curves show a significantly reduced free survival from DUs in patients with increased resistin (p = 0.002). In multivariate analysis, resistin is associated with the development of new DUs. Increased serum resistin level is a predictive marker of new DUs in SSc.

Identifiants

pubmed: 34462844
doi: 10.1007/s10238-021-00756-2
pii: 10.1007/s10238-021-00756-2
pmc: PMC9338111
doi:

Substances chimiques

Biomarkers 0
RETN protein, human 0
Resistin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

421-426

Informations de copyright

© 2021. The Author(s).

Références

J Rheumatol. 2015 Oct;42(10):1808-16
pubmed: 26276964
J Rheumatol. 2009 Jul;36(7):1470-6
pubmed: 19487271
Cell Mol Immunol. 2006 Feb;3(1):29-34
pubmed: 16549046
Ann Rheum Dis. 2001 Jun;60(6):592-8
pubmed: 11350848
Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):144-150
pubmed: 28980898
Clin Exp Immunol. 2021 Aug;205(2):128-134
pubmed: 33876421
Circulation. 2003 Aug 12;108(6):736-40
pubmed: 12874180
PLoS One. 2013 Dec 27;8(12):e84576
pubmed: 24386395
Mol Cell Endocrinol. 2010 Mar 25;316(2):129-39
pubmed: 19723556
Arthritis Rheum. 2004 Dec;50(12):3985-93
pubmed: 15593188
Biochem Biophys Res Commun. 2012 Jun 1;422(2):321-6
pubmed: 22575502
Arthritis Rheum. 2009 May 15;61(5):688-94
pubmed: 19405007
Arch Dermatol Res. 2020 Aug;312(6):453-458
pubmed: 31667578
J Rheumatol. 2007 Dec;34(12):2423-30
pubmed: 17985402
Rheumatology (Oxford). 2017 Jan;56(1):14-25
pubmed: 27094599
Arthritis Care Res (Hoboken). 2014 Sep;66(9):1380-5
pubmed: 24515659
J Rheumatol. 1988 Feb;15(2):202-5
pubmed: 3361530
Rheumatol Int. 2014 Aug;34(8):1165-70
pubmed: 24141536
Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii3-7
pubmed: 19487220
J Rheumatol. 2000 Jan;27(1):155-60
pubmed: 10648032
Clin Exp Rheumatol. 2003;21(3 Suppl 29):S42-6
pubmed: 12889222
Rheumatology (Oxford). 2010 Jul;49(7):1374-82
pubmed: 20400463
Arch Dermatol Res. 2019 May;311(4):251-263
pubmed: 30806766
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18
pubmed: 28516167
Acta Reumatol Port. 2015 Apr-Jun;40(2):156-62
pubmed: 26219969
Circulation. 2000 Oct 31;102(18):2165-8
pubmed: 11056086
N Engl J Med. 2009 May 7;360(19):1989-2003
pubmed: 19420368
Nat Rev Immunol. 2006 Oct;6(10):772-83
pubmed: 16998510
Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S47-54
pubmed: 26243652
Pharmacol Res. 2011 Jun;63(6):504-11
pubmed: 21419223
Ann Rheum Dis. 2011 Jan;70(1):32-8
pubmed: 20805294
Eur J Rheumatol. 2020 Oct;7(Suppl 3):S165-S172
pubmed: 33164731

Auteurs

Chiara Pellicano (C)

Department of Translational and Precision Medicine, Lazio, Sapienza University of Rome, Viale dell'Università 37, 00185, Rome, Italy.

Giorgia Leodori (G)

Department of Translational and Precision Medicine, Lazio, Sapienza University of Rome, Viale dell'Università 37, 00185, Rome, Italy.

Amalia Colalillo (A)

Department of Translational and Precision Medicine, Lazio, Sapienza University of Rome, Viale dell'Università 37, 00185, Rome, Italy.

Luca Navarini (L)

Unit of Allergology, Clinical Immunology and Rheumatology, Department of Medicine, Campus Bio-Medico University, Rome, Italy.

Antonietta Gigante (A)

Department of Translational and Precision Medicine, Lazio, Sapienza University of Rome, Viale dell'Università 37, 00185, Rome, Italy.

Edoardo Rosato (E)

Department of Translational and Precision Medicine, Lazio, Sapienza University of Rome, Viale dell'Università 37, 00185, Rome, Italy. edoardo.rosato@uniroma1.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH